Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Ultrasound Guidance Removes 510(k) Special Report Recommendation

This article was originally published in The Gray Sheet

Executive Summary

An ultrasound manufacturer no longer needs to submit a "510(k) special report" prior to shipping a new device as long as it keeps appropriate records in its design history file, according to an FDA 1guidance issued Sept. 9

You may also be interested in...



Current Fetal Ultrasound Practices Could Increase Risks, Studies Suggest

A sharp increase in the use of fetal ultrasounds in recent years in women with healthy pregnancies from an average of 2 scans to 5 scans per pregnancy and recent warnings from medical societies could prompt FDA to look more closely at possible risks to the fetus from ultrasound.

DIAGNOSTIC ULTRASOUND 510(k)S COULD INCLUDE THIRD-PARTY CERTIFICATION IN LIEU OF CERTAIN SAFETY DATA, FDA SAYS IN DRAFT REVISED GUIDANCE DOCUMENT

Manufacturers of diagnostic ultrasound systems could submit third-party certification of compliance to certain voluntary standards in 510(k)s instead of submitting actual performance data covered by the standards under draft revisions to FDA's guidance document for diagnostic ultrasound systems and transducers.

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel